NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2018-12-20
Impressions: 160 Article
Following the footsteps of companies like Novartis, Merck KGaA, and now GSK and Pfizer, Bristol-Myers Squibb (BMS) also announced its exit from consumer health. Japanese drugmaker Taisho Japanese drugmaker Taisho will buy BMS’ French OTC division, known as Upsa, for US$ 1.6 billion.
The company spokeswoman said “no decision on the future of the business has been made,” and the company “may also ultimately determine to retain and grow the business."
BMS has been looking to offload the unit since June, when it announced a strategic review. Since then, there have been rumors that players such as Stada and Procter & Gamble could come forth to nab Upsa, which sells painkillers, sleep drugs and more.
Taisho and BMS have done business together in the past. In 2009, the Japanese drugmaker inked a pact to buy part of Bristol’s Asia-Pacific OTC business for US$ 310 million, Bloomberg noted.
Meanwhile, Eli Lilly is now focusing on its next big bet after its new CGRP migraine drug Emgality (galcanezumab) won the FDA approval in September this year. Last week, Eli Lilly announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes.
Lilly has been actively hunting up a slate of new deals to beef up its pipeline. Recently, it signed a deal with biopharma company AC Immune for close to US$ 2 billion for a portfolio of preclinical tau aggregation inhibitors, or drugs for Alzheimer’s disease.
Lilly has faced many failures in the past with Alzheimer’s. But the company never withdrew its efforts to search a drug that can slow or halt the progress of the memory-wasting ailment, which afflicts millions.
Merck to buy Antellique: Merck & Co is all set to buy animal health firm Antelliq Group for US$ 2.4 billion in a bid to bolster this fast-growing business unit.
Antelliq, which is majority-owned by private investors BC Partners, makes digital identification products for livestock. Merck is acquiring this business for US$ 2.74 billion (Euro 2.4 billion).
Merck
said Antelliq will be a wholly owned and separately operated subsidiary within
its animal health division.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
